Joint and tendon recovery
1A small retrospective knee-pain report exists; it does not establish structural tissue repair.
What does it do?
An experimental 15-residue peptide discussed for repair and digestive health; most efficacy evidence is animal research.
Approved & studied uses
Community uses Reported, unvalidated
Wound / tissue
23Tendon, ligament, muscle and vascular repair claims.
Neurological
23Brain ischemia, spinal injury, peripheral nerves, cognition and stress-response hypotheses.
Gastrointestinal
23Gastric/duodenal ulcers, intestinal inflammation, mucosal repair and barrier function; oral/systemic claims exceed established human evidence.
Reasons people report using it; these do not establish benefit.23
Evidence limits
View research →Whether benefits exceed placebo, natural recovery, or usual treatment.1
8 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Immune and impurity concerns
FDA flags immunogenicity and peptide-impurity concerns.3
No FDA-approved BPC-157 product.
Molecular information
Amino-acid sequence
- Gly
- Glu
- Pro
- Pro
- Pro
- Gly
- Lys
- Pro
- Ala
- Asp
- Asp
- Ala
- Gly
- Leu
- Val
15 residues · N → C4
Length15 amino acids
Molecular weight · Da1,419.5 Da
Formula, sequence notation & identity
Molecular formulaC62H98N16O224
G–E–P–P–P–G–K–P–A–D–D–A–G–L–VFree N- and C-termini in the cited identity.
H-GEPPPGKPADDAGLV-OH
Free peptide identity; acetate and other salt formulations have additional components.
Pep-Pedia identity details
15 amino acids · 1,419.53 Da
Gly-Lys-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-ValReference description; checked chemical identity above takes precedence when available.23
Pharmacokinetics
How long does it stay in the body?
Animal dataNot a human half-life
Reported half-life15.2 minutes22
Route / formulationSingle intravenous administration
Mean intact BPC-157 elimination half-life after a single IV administration. This is an animal measurement, not a human prediction.
50%of reference level
Illustrative model using animal measurements.
About 3% remaining after 1.27 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Sprague-Dawley rats; n = 6
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Animal dataNot a human half-life
Reported half-life5.27 minutes22
Route / formulationSingle intravenous administration
Intact-peptide elimination in dogs after a single IV administration. Species and route differ from human community use.
50%of reference level
Illustrative model using animal measurements.
About 3% remaining after 26.35 min
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Beagle dogs; n = 6
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life4 hrs21
Route / formulationSource page: Injectable. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 20 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Sikiric et al. various studies
Source’s reported peak time: 1 hr. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life2 hrs21
Route / formulationSource page: Oral. Exact PK route not verified.
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 10 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Sikiric et al. various studies
Source’s reported peak time: 1 hr. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Pain reports are preliminary
11 of 12 BPC-only respondents reported improvement; retrospective telephone follow-up cannot establish causation.1
No measured short-term signal in two people
The IV pilot reported no adverse events or measured biomarker changes. Its size and brief follow-up cannot establish safety.2
Reported timelines
Reference & communityWeeks 1–2 / 2–4 / 4–8
Reference/community sequence: pain/inflammation or digestive comfort; repair/barrier changes; maximum/systemic benefits. Not validated human recovery estimates.23
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Duration of use
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 22 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 28 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 12 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “3834 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| IVIntravenous infusion over one hour | 10 mg | Once on day 1 | Short-term infusion safetyHuman study | Day 1 | 2 |
Population Two adults previously exposed to IV BPC-157 Context Experimental clinic exposure; no control group and no efficacy endpoint. Source dose wording 10 mg on day 1; 20 mg on day 2 | |||||
| IVIntravenous infusion over one hour | 20 mg | Once on day 2 | Short-term infusion safetyHuman study | Day 2 | 2 |
Population Two adults previously exposed to IV BPC-157 Context Experimental clinic exposure; no control group and no efficacy endpoint. Source dose wording 10 mg on day 1; 20 mg on day 2 | |||||
| SubQSubQ near injury | 250-500 mcg | 1-2x daily | Tendon/Joint healingReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQSubQ near injury | 500-1000 mcg | 2x daily | Serious injuryReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQSubcutaneous | 250-500 mcg | 1-2x daily | General healingReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording SubQ or IM Source tabs Injectable | |||||
| IMIntramuscular | 250-500 mcg | 1-2x daily | General healingReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording SubQ or IM Source tabs Injectable | |||||
| SubQ | 250 mcg | 1x daily | MaintenanceReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| OralOral (empty stomach) | 500 mcg-1 mg | 1-2x daily | Gastric protectionReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (empty stomach) | 1-2 mg | 1-2x daily | General healingReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (empty stomach) | 500 mcg | 2x daily | Ulcer preventionReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral (empty stomach) | 500 mcg | 1x daily | MaintenanceReference report | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-12 weeks
- Break
- 4+ weeks
Reported timing
Empty stomach preferred
Oral
- Use period
- 4-12 weeks
- Break
- 4+ weeks
Reported timing
Empty stomach, 30 min before meals
Side effects & safety
Immune and impurity concerns
FDA flags immunogenicity and peptide-impurity concerns.
3Rare or delayed harms unresolved
A two-person, three-day observation cannot quantify uncommon or long-term adverse effects.
2Human benefit remains uncertain
The knee report had no control group or objective tissue-healing measure.
1Recent FDA review
The assessment describes injection-site reactions, shortness of breath and a pigmentation reaction with a BPC-157/TB-500 product; causality and ingredient attribution remain limited.
7Symptoms
Persistent redness, infection, swelling/rash, severe headache/dizziness, worsening digestion or abdominal pain need assessment.
Limitations
Blood-thinner interactions and pregnancy/lactation safety unresolved.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
9 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Blood thinners
Caution reportedInteraction evidence limited.23
Reference report · Evidence context: Caution claimTB-500
Unverified pairingHealing rationale.23
Reference report · Pep-Pedia label: SynergisticGHRP-6
Unverified pairingNo validated combination.23
Reference report · Pep-Pedia label: CompatibleIpamorelin
Unverified pairingGH-receptor rationale.23
Reference report · Pep-Pedia label: SynergisticCJC-1295
Unverified pairingGH-receptor rationale.23
Reference report · Pep-Pedia label: SynergisticMelanotan II
Unverified pairingDifferent claimed receptor targets; combination untested.23
Reference report · Pep-Pedia label: CompatibleAOD-9604
Unverified pairingReported repair/fat-metabolism pairing; safety and efficacy unestablished.23
Reference report · Pep-Pedia label: CompatibleL-carnitine
Unverified pairingProposed tissue-repair/energy-metabolism complement; untested.23
Reference report · Pep-Pedia label: CompatibleTB-500 / thymosin β4 combinations
Not establishedFour patients in the knee report received BPC-157 with thymosin β4. That uncontrolled subgroup cannot establish an interaction, synergy, or safety.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
The IV pilot used saline infusion; it provides no validated home-vial preparation or storage rule.29
Published preparation
Each study dose was diluted in 250 mL normal saline and infused in a clinic. This is a description of that experiment.2
Research-vial gap
The cited catalog identifies acetate quantities, not a clinically validated bacteriostatic-water volume or beyond-use date.9
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia distinguishes mixed solution from unopened dry powder.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Mixed solution: reported 2–6°C and 28 days. · Dry powder: reported −20°C or below, sealed and protected from light.
The source describes gentle mixing and avoiding vigorous shaking.
The source also claims multi-year dry-powder stability without a product-specific stability study.
Oral
The oral section describes capsules or measured powder, not vial reconstitution.
- Form
- Source describes a prepared product
- Reported parameters
- Reported timing: empty stomach, 30 minutes before food. · Capsule storage: cool, dry room-temperature conditions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite, Fluffy CakeReported appearanceClear Solution After ReconstitutionReported variationSlight ClumpingReported concernCollapsed or Melted AppearanceReported concernCloudy After Reconstitution
23Vial sizes
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Full storage notes from Pep-Pedia
23Fridge 2-6°C, use within 28 days
Room temp, cool dry place
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Limited human dataCompound identity & other names
An experimental 15-amino-acid peptide studied mainly in laboratory and animal injury models. Small uncontrolled human reports do not establish that it repairs tendons, treats gut disease, or is safe for self-injection.
Other names: BPC157 · BPC 157 · Body Protection Compound 157 · PL 14736
No FDA-approved BPC-157 product.
How it may work
Angiogenesis, collagen and growth-factor signaling are proposed mechanisms; human route superiority is unestablished.23
Uncontrolled knee-pain reports
In a retrospective clinic report, 11 of 12 patients receiving BPC-157 alone reported improvement after a knee injection. There was no control group, standardized functional assessment, or imaging confirmation of healing.
1Two-person safety pilot
Two adults previously exposed to BPC-157 reported no side effects after two IV infusions; measured blood markers showed no meaningful changes. This sample cannot establish safety or rule out uncommon harms.
2Source checks & newer research
FDA: compounding safety concerns
FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
FDA compounding safety statement; checked24Research areas and evidence gaps
Joint and tendon recovery. A small retrospective knee-pain report exists; it does not establish structural tissue repair.1
- Whether benefits exceed placebo, natural recovery, or usual treatment.
- Long-term effects, interactions, and reliable human pharmacokinetics across routes.
- Whether online material matches material used in a published study.
Community reports Unvalidated
Pep-Pedia describes injury and gut-related use. Its protocol tables are secondary reports, not results of a dose-finding trial.8
No representative sample or verified outcomes supports these schedules; dose, product identity, co-use, and rehabilitation vary.
Search coverage and review status
Additional recent evidence was checked, including FDA assessment: BPC-157 free base and acetate. See individual source summaries for findings and limitations.
- Checked
- 2026-10-12
- Search
- BPC 157 2025 2026 human clinical study PubMed
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainAbstract checked
AI-PREPARED SUMMARY
Retrospective telephone follow-up: 11 of 12 BPC-only recipients reported pain improvement. No comparator or objective healing endpoint; a hypothesis-generating case series.
Uncontrolled knee-pain reports
In a retrospective clinic report, 11 of 12 patients receiving BPC-157 alone reported improvement after a knee injection. There was no control group, standardized functional assessment, or imaging confirmation of healing.
2Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyAbstract checked
AI-PREPARED SUMMARY
Two previously exposed adults received 10 mg then 20 mg IV on consecutive days. No reported adverse effects or tested biomarker changes; the tiny, brief study cannot establish general safety.
Two-person safety pilot
Two adults previously exposed to BPC-157 reported no side effects after two IV infusions; measured blood markers showed no meaningful changes. This sample cannot establish safety or rule out uncommon harms.
3FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
FDA identifies unresolved human safety and product-characterization concerns for BPC-157.
4PubChem: BPC-157 molecular identityAbstract checked
AI-PREPARED SUMMARY
Registry entry for the 15-residue free peptide; a salt or excipient-containing powder has a different total composition.
5BPC-157 pharmacokinetics in rats and dogsAbstract checked
AI-PREPARED SUMMARY
Parent BPC-157 cleared rapidly in rat and dog IV/IM experiments. These data do not provide a human half-life.
6BPC-157 pharmacokinetics in rats and dogsAbstract checked
AI-PREPARED SUMMARY
Parent BPC-157 cleared rapidly in rat and dog IV/IM experiments. These data do not provide a human half-life.
Pep-Pedia bibliography · Checked 2026-10-12
7FDA assessment: BPC-157 free base and acetatePrimary source checked
AI-PREPARED SUMMARY
FDA reviewed sparse clinical studies and route-specific safety gaps; spontaneous adverse-event reports cannot establish event rates or causality.
Additional research · Checked 2026-10-12
8Pep-Pedia: bpc-157 community protocol referenceCommunity source checked
AI-PREPARED SUMMARY
The profile publishes commonly discussed schedules. It is used here to document community conventions, not validate benefit or dosage.
9BIOZOL / MedChemExpress BPC 157 acetate catalogCatalog checked
AI-PREPARED SUMMARY
Catalog identifiers include 5 mg and 10 mg research quantities. A label amount is not a dose, clinical approval, or verification of an individual batch.
10Sikiric, P., Hahm, K.B., Blagaic, A.B., et al. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection. Gut and Liver, 14(2), 153-167.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat stomach-injury models showed less ulcer damage and improved mucosal repair across tested conditions.
Reported population / model
Rats
Reported study details
Multiple routes tested · Various durations · Cytoprotective effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Xu, C., Sun, L., Ren, F., et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 114, 104665.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The animal toxicology report describes no serious treatment-related findings under its test conditions; that does not establish human safety.
Reported population / model
Multiple species
Reported study details
Up to 1000 μg/kg · 90 days · Comprehensive toxicology
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Perovic, D., Kolenc, D., Bilic, V., et al. (2019). Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research, 14(1), 199.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Injured rats reportedly recovered more function and had less spinal tissue damage during 30 days of treatment.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 30 days · Improved functional recovery
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13Hsieh, M.J., Liu, H.T., Wang, C.N., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 95(3), 323-333.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Laboratory findings linked BPC-157 to increased VEGFR2 activity and blood-vessel formation; clinical benefit remains unestablished.
Reported population / model
In vitro and in vivo
Reported study details
Various concentrations · VEGFR2 activation measured
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Staresinic, M., Petrovic, I., Novinscak, T., et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research, 24(5), 1109-1117.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat quadriceps injuries reportedly showed improved tissue appearance, inflammation measures and function.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 28 days · Enhanced muscle regeneration
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
15Staresinic, M., Sebecic, B., Patrlj, L., et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976-983.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Transected rat Achilles tendons reportedly recovered better mechanical and functional measures; this is not evidence for a human regimen.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 14 days · Significant improvement in tendon healing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16Jóźwiak, M., Bauer, M., Kamysz, W., Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals, 18(2), 185.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
17Seiwerth, S., Milavic, M., Vukojevic, J., et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 12, 627533.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
18Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
19Sikiric, P., Seiwerth, S., Rucman, R., et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612-1632.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
20Vukojevic, J., Milavić, M., Perović, D., et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482-487.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
21Pep-Pedia: BPC-157 — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 4 hrs and a peak time of 1 hr. Stated attribution: Sikiric et al. various studies. This 4-hour reference claim differs from measured intact-peptide elimination in rats and dogs (under 30 minutes). It is not a validated human half-life. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
22BPC-157: measured rat and dog pharmacokinetics (full text)Primary source checked
AI-PREPARED SUMMARY
Single IV dosing produced a mean intact-peptide elimination half-life of 15.2 minutes in rats and 5.27 minutes in dogs. IV/IM experiments reported values below 30 minutes. These animal measurements do not supply a human half-life or an effect duration.
23Pep-Pedia: BPC-157 — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
24FDA: compounding safety concernsPrimary source checked
AI-PREPARED SUMMARY
FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
FDA: compounding safety concerns
FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
Additional primary-source check · Checked 2026-10-12